Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide signed informed consent (by parent or legal guardian if the subject is a minor) and informed assent if applicable~* Age 6 to 21 years~* Must have history of symptomatic reactivity to cow's milk (eczema, urticaria, upper/lower resp., GI, other associated rash, oral symptoms)~* History of positive skin prick test (wheal \>/= histamine control) or milk-Immunoglobulin E (IgE)\>0.35 kilounits per liter (kU/L)~* Positive DBPCFC~* All females of child bearing age must be using appropriate birth control~Exclusion Criteria:~* History of anaphylaxis requiring hospitalization~* History of intubation related to asthma~* Has the ability to tolerate \>2.4gram of milk protein at initial DBPCFC~* Has a history of allergy to any component of vehicle~* Pregnancy (need negative test)~* Viral upper respiratory infection (URI) or gastroenteritis within 7days of OFC (OFC needs to be rescheduled)~* Has pulmonary function tests \<80% of predicted (FEV1) or clinical history consistent with moderate persistent asthma~* Currently taking greater than medium dose inhaled corticosteroid (\>400mcg/day fluticasone or fluticasone equivalent if \</=12yo or \>600mcg/day if \>12 years old)~* Antihistamine within 1 week prior to skin testing or food challenges (Skin testing and/or food challenge needs to be rescheduled)~* Systemic corticosteroid within 4 weeks prior to baseline visit~* Receiving omalizumab, beta-blocker, Angiotensin-converting enzyme (ACE) inhibitor or tricyclic antidepressant therapy~* Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy (e.g., heart disease, diabetes)~* Participation in any interventional study for treatment of a food allergy in the past 12 months~* Severe reaction at initial DBPCFC, defined as:~  i. Life-threatening anaphylaxis ii. Requires overnight hospitalization

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Active Treatment (Type: EXPERIMENTAL): Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).